GLP-1/GIP agonists and cancer: mechanisms, evidence, and nutrition implications

Obesity and diabetes increase cancer risk through insulin resistance, chronic inflammation, and altered growth signaling. Glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists reshape this metabolic milieu and are increasingly used for weight loss and glycemic control. Uncertainty persists about whether these agents influence cancer incidence or progression, and there is no consensus on nutrition care during therapy. We present a narrative, mechanism-to-clinic review that synthesizes randomized and observational human studies alongside translational evidence on insulin/IGF-1 pathways, adipokines, bile acids, and the microbiota. We also integrate practice-focused guidance on preserving lean mass, monitoring micronutrients, and managing gastrointestinal tolerance while on these agents. Current human evidence does not show a consistent increase in overall cancer risk with these therapies; however, signals are heterogeneous across tumor sites and follow-up remains limited. Randomized trials rarely adjudicate cancer outcomes, and pharmacovigilance and preclinical results are mixed and context-dependent. Weight loss and improved insulin sensitivity plausibly reduce pro-tumorigenic signaling, whereas rapid weight reduction may threaten muscle mass unless accompanied by proactive nutrition support and resistance exercise. Available data suggest no uniform carcinogenic signal from GLP-1/GIP therapies to date, but organ-specific effects and long-term safety require rigorous, adequately powered follow-up. Dietitians and oncology teams should co-manage patients using high-quality protein distributed across meals, fiber-rich, low-glycemic dietary patterns (such as Mediterranean-style eating), resistance exercise, and targeted micronutrient monitoring, alongside standardized recording of cancer-relevant outcomes.